|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DCP2 |
Gene summary for DCP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DCP2 | Gene ID | 167227 |
| Gene name | decapping mRNA 2 | |
| Gene Alias | NUDT20 | |
| Cytomap | 5q22.2 | |
| Gene Type | protein-coding | GO ID | GO:0000184 | UniProtAcc | Q8IU60 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 167227 | DCP2 | LZE4T | Human | Esophagus | ESCC | 3.93e-11 | 2.38e-01 | 0.0811 |
| 167227 | DCP2 | LZE5T | Human | Esophagus | ESCC | 8.02e-03 | 1.63e-01 | 0.0514 |
| 167227 | DCP2 | LZE7T | Human | Esophagus | ESCC | 1.02e-10 | 3.43e-01 | 0.0667 |
| 167227 | DCP2 | LZE8T | Human | Esophagus | ESCC | 4.56e-05 | 1.77e-01 | 0.067 |
| 167227 | DCP2 | LZE24T | Human | Esophagus | ESCC | 3.51e-20 | 4.30e-01 | 0.0596 |
| 167227 | DCP2 | LZE6T | Human | Esophagus | ESCC | 6.16e-08 | 1.78e-01 | 0.0845 |
| 167227 | DCP2 | P1T-E | Human | Esophagus | ESCC | 8.00e-06 | 3.91e-01 | 0.0875 |
| 167227 | DCP2 | P2T-E | Human | Esophagus | ESCC | 6.75e-36 | 7.87e-01 | 0.1177 |
| 167227 | DCP2 | P4T-E | Human | Esophagus | ESCC | 1.54e-12 | 3.49e-01 | 0.1323 |
| 167227 | DCP2 | P5T-E | Human | Esophagus | ESCC | 3.55e-09 | 1.97e-01 | 0.1327 |
| 167227 | DCP2 | P8T-E | Human | Esophagus | ESCC | 1.40e-14 | 3.51e-01 | 0.0889 |
| 167227 | DCP2 | P9T-E | Human | Esophagus | ESCC | 2.65e-17 | 2.26e-01 | 0.1131 |
| 167227 | DCP2 | P10T-E | Human | Esophagus | ESCC | 1.62e-22 | 4.70e-01 | 0.116 |
| 167227 | DCP2 | P11T-E | Human | Esophagus | ESCC | 4.09e-06 | 2.20e-01 | 0.1426 |
| 167227 | DCP2 | P12T-E | Human | Esophagus | ESCC | 2.10e-17 | 3.08e-01 | 0.1122 |
| 167227 | DCP2 | P15T-E | Human | Esophagus | ESCC | 2.28e-25 | 5.86e-01 | 0.1149 |
| 167227 | DCP2 | P16T-E | Human | Esophagus | ESCC | 6.00e-13 | 1.40e-01 | 0.1153 |
| 167227 | DCP2 | P17T-E | Human | Esophagus | ESCC | 4.59e-02 | 2.56e-01 | 0.1278 |
| 167227 | DCP2 | P19T-E | Human | Esophagus | ESCC | 2.85e-06 | 3.75e-01 | 0.1662 |
| 167227 | DCP2 | P20T-E | Human | Esophagus | ESCC | 1.96e-16 | 3.80e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190331316 | Esophagus | ESCC | positive regulation of mRNA metabolic process | 87/8552 | 118/18723 | 5.10e-10 | 1.32e-08 | 87 |
| GO:006101319 | Esophagus | ESCC | regulation of mRNA catabolic process | 115/8552 | 166/18723 | 5.90e-10 | 1.49e-08 | 115 |
| GO:004348719 | Esophagus | ESCC | regulation of RNA stability | 117/8552 | 170/18723 | 7.91e-10 | 1.94e-08 | 117 |
| GO:0010639110 | Esophagus | ESCC | negative regulation of organelle organization | 215/8552 | 348/18723 | 8.20e-10 | 2.01e-08 | 215 |
| GO:000700418 | Esophagus | ESCC | telomere maintenance via telomerase | 56/8552 | 69/18723 | 1.40e-09 | 3.30e-08 | 56 |
| GO:004348819 | Esophagus | ESCC | regulation of mRNA stability | 109/8552 | 158/18723 | 2.40e-09 | 5.35e-08 | 109 |
| GO:00903053 | Esophagus | ESCC | nucleic acid phosphodiester bond hydrolysis | 163/8552 | 261/18723 | 3.07e-08 | 5.73e-07 | 163 |
| GO:001083319 | Esophagus | ESCC | telomere maintenance via telomere lengthening | 61/8552 | 81/18723 | 5.24e-08 | 9.37e-07 | 61 |
| GO:00322108 | Esophagus | ESCC | regulation of telomere maintenance via telomerase | 43/8552 | 53/18723 | 1.20e-07 | 1.95e-06 | 43 |
| GO:000018414 | Esophagus | ESCC | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 32/8552 | 37/18723 | 2.96e-07 | 4.23e-06 | 32 |
| GO:000627816 | Esophagus | ESCC | RNA-dependent DNA biosynthetic process | 56/8552 | 75/18723 | 3.03e-07 | 4.30e-06 | 56 |
| GO:006101416 | Esophagus | ESCC | positive regulation of mRNA catabolic process | 63/8552 | 87/18723 | 3.70e-07 | 5.15e-06 | 63 |
| GO:006115716 | Esophagus | ESCC | mRNA destabilization | 61/8552 | 84/18723 | 4.81e-07 | 6.49e-06 | 61 |
| GO:00905033 | Esophagus | ESCC | RNA phosphodiester bond hydrolysis, exonucleolytic | 35/8552 | 42/18723 | 5.35e-07 | 7.11e-06 | 35 |
| GO:190435616 | Esophagus | ESCC | regulation of telomere maintenance via telomere lengthening | 47/8552 | 61/18723 | 5.61e-07 | 7.40e-06 | 47 |
| GO:005077916 | Esophagus | ESCC | RNA destabilization | 63/8552 | 88/18723 | 7.23e-07 | 9.40e-06 | 63 |
| GO:20012513 | Esophagus | ESCC | negative regulation of chromosome organization | 60/8552 | 86/18723 | 5.20e-06 | 5.45e-05 | 60 |
| GO:00002913 | Esophagus | ESCC | nuclear-transcribed mRNA catabolic process, exonucleolytic | 18/8552 | 19/18723 | 8.00e-06 | 7.78e-05 | 18 |
| GO:009067015 | Esophagus | ESCC | RNA localization to Cajal body | 18/8552 | 19/18723 | 8.00e-06 | 7.78e-05 | 18 |
| GO:009067115 | Esophagus | ESCC | telomerase RNA localization to Cajal body | 18/8552 | 19/18723 | 8.00e-06 | 7.78e-05 | 18 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301824 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
| hsa0301834 | Esophagus | ESCC | RNA degradation | 62/4205 | 79/8465 | 1.18e-07 | 9.39e-07 | 4.81e-07 | 62 |
| hsa030182 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa030183 | Liver | HCC | RNA degradation | 58/4020 | 79/8465 | 2.29e-06 | 2.19e-05 | 1.22e-05 | 58 |
| hsa030189 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
| hsa0301814 | Oral cavity | OSCC | RNA degradation | 59/3704 | 79/8465 | 2.05e-08 | 1.91e-07 | 9.70e-08 | 59 |
| hsa0301841 | Oral cavity | EOLP | RNA degradation | 22/1218 | 79/8465 | 1.33e-03 | 4.80e-03 | 2.83e-03 | 22 |
| hsa0301851 | Oral cavity | EOLP | RNA degradation | 22/1218 | 79/8465 | 1.33e-03 | 4.80e-03 | 2.83e-03 | 22 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DCP2 | SNV | Missense_Mutation | rs776321450 | c.1072N>T | p.Arg358Trp | p.R358W | Q8IU60 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.88) | TCGA-C5-A7CK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| DCP2 | SNV | Missense_Mutation | c.555N>C | p.Lys185Asn | p.K185N | Q8IU60 | protein_coding | deleterious(0.01) | benign(0.061) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| DCP2 | SNV | Missense_Mutation | rs369278042 | c.517C>T | p.Arg173Cys | p.R173C | Q8IU60 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| DCP2 | SNV | Missense_Mutation | c.1234N>G | p.Asn412Asp | p.N412D | Q8IU60 | protein_coding | tolerated_low_confidence(1) | benign(0.001) | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| DCP2 | SNV | Missense_Mutation | novel | c.799N>G | p.Lys267Glu | p.K267E | Q8IU60 | protein_coding | tolerated(0.07) | probably_damaging(0.979) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| DCP2 | SNV | Missense_Mutation | c.683N>T | p.Ala228Val | p.A228V | Q8IU60 | protein_coding | tolerated(1) | benign(0.014) | TCGA-AG-A02N-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | folinic | CR | |
| DCP2 | SNV | Missense_Mutation | rs748555203 | c.809N>A | p.Arg270Gln | p.R270Q | Q8IU60 | protein_coding | tolerated(0.11) | benign(0.058) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| DCP2 | SNV | Missense_Mutation | novel | c.968N>A | p.Arg323Lys | p.R323K | Q8IU60 | protein_coding | tolerated_low_confidence(0.54) | benign(0.045) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| DCP2 | deletion | In_Frame_Del | c.1119_1121delTAG | p.Ser376del | p.S376del | Q8IU60 | protein_coding | TCGA-DC-6157-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |||
| DCP2 | SNV | Missense_Mutation | novel | c.145N>G | p.Phe49Val | p.F49V | Q8IU60 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |